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Abstract 1 
The increasing prevalence of obesity and its comorbidities represents a major threat to human health 2 
globally. Pharmacological treatments exist to achieve weight loss, but the subsequent weight maintenance 3 
is prone to fail in the long run. Accordingly, efficient new strategies to persistently control body weight 4 
need to be elaborated. Exercise and dietary interventions constitute classical approaches to reduce and 5 
maintain body weight, yet people suffering from metabolic diseases are often unwilling or unable to move 6 
adequately. The administration of drugs that partially mimic exercise adaptation might circumvent this 7 
problem by easing and supporting physical activity. The thermogenic peroxisome proliferator-activated 8 
receptor γ coactivator 1α (PGC-1α) largely mediates the adaptive response of skeletal muscle to endurance 9 
exercise and is a potential target for such interventions. Here, we review the role of PGC-1α in mediating 10 
exercise adaptation, coordinating metabolic circuits and enhancing thermogenic capacity in skeletal 11 
muscle. We suggest a combination of elevated muscle PGC-1α and exercise as a modified approach for 12 
the efficient long-term control of body weight and the treatment of the metabolic syndrome. 13 
 14 




Metabolic disorders are increasingly recognized as major threats to public health. Almost two thirds of the 18 
adult Americans are already overweight (body mass index >25 kg m−2) and the prevalence will 19 
presumably rise in the future1. Projections indicate that 86.3% of the adult American population will be 20 
overweight and 51.1% will even have to be classified as obese (body mass index >30 kg m−2) by the year 21 
20302. Importantly, excessive body weight fosters the development of comorbidities such as hypertension, 22 
dyslipidemia, cancer, cardiovascular disease and diabetes3, 4_ENREF_2.  23 
A protracted energy imbalance where energy intake exceeds expenditure is considered as a key element in 24 
the etiology of metabolic impairments5, 6. Reducing energy intake (by nutritional intervention), increasing 25 
energy expenditure (by physical activity) or the combination of both thus constitute cornerstones in the 26 
treatment of metabolic disorders7. Such lifestyle interventions generally lead to weight loss initially 7 and 27 
improve metabolic parameters8, but the majority of patients regain their weight in the long run9, 10. A meta-28 
analysis of studies published between 1931 and 1999 reveals a median success rate to maintain body 29 
weight after weight loss of a moderate 15%11. This impressive recidivism rate after otherwise successful 30 
weight loss is partially due to poor adherence to lifestyle interventions and potently facilitated by 31 
coordinate actions of ancestral physiological responses designed to powerfully defend and restore body 32 
energy stores12.  33 
Indeed, weight loss initiated by reduced energy intake rapidly turns on a “thrifty” program which favors 34 
the eventual restoration of energy stores (Figure 1, outer circle)13. To this end, energy expenditure is 35 
suppressed in skeletal muscle, which is an important site of energy conservation during food restriction14. 36 
Concomitantly, adipose tissue increases its responsiveness towards the action of insulin15. Upon energy re-37 
availability, energy is diverted from muscle to adipose tissue for accelerating fat mass replenishment13, 15, 38 
16_ENREF_10. While such adaptive traits allowed the hunter-gatherers to deal with intermittent periods of 39 
famine and feast, and had thus survival value during human evolution, they nowadays strongly counteract 40 
any attempt to maintain body weight following successful weight loss17. 41 
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Similarly, the life of hunter-gatherers was characterized by alternating periods of high physical activity 42 
(hunting and searching for food) and rest (Figure 1, inner circle). Although these habitual physical 43 
activity-rest cycles have a shorter term (hours) compared with feast-famine cycles (days), the underlying 44 
mechanisms are reminiscent of those that operate during famine and feast18. During physical activity 45 
muscle energy stores like glycogen and triglycerides are depleted, but subsequently replenished in the 46 
resting phase. Such oscillations of muscle glycogen and triglyceride levels with physical activity-rest 47 
cycles during tens of thousands of years resulted in the selection of a “thrifty” program with a high 48 
proficiency to restore muscle energy stores. A decreased turn-over in muscle glycogen and 49 
intramyocellular lipids (IMCLs) is postulated to ultimately impair skeletal muscle insulin sensitivity18, 50 
19_ENREF_17. 51 
A successful long-term body weight control, with concomitant prevention of metabolic derangements, 52 
consequently has to fulfill two requirements: a) avoidance of energy conservation in muscle tissue 53 
following weight loss in order to prevent obesity relapse and b) regular metabolic cycling in skeletal 54 
muscle in order to prevent excessive accumulation of glycogen and lipids.  55 
Intriguingly, life-long regular exercise would meet both demands (Figure 1), but the long-term adherence 56 
is prone to failure. Exercise pills that mimic the plastic adaptations to exercise would be an alternative 57 
treatment of choice, but the high complexity of exercise hampers the unraveling and pinpointing of a 58 
single pathway that mimics all effects of exercise20, 21_ENREF_19. Nonetheless, targeting key mediators of 59 
physical activity in skeletal muscle constitutes a promising approach to support, facilitate and/or amplify 60 
the effects of exercise in manipulating energy expenditure, promoting metabolic cycling and thus finally 61 
controlling body weight and promoting metabolic health. In the following section, we will outline why the 62 
peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) represents an excellent target and 63 
summarize the central role of PGC-1α in mediating exercise adaptation, coordinating metabolic circuits 64 
and enhancing thermogenic capacity in skeletal muscle. 65 
PGC-1α is a central, integrative hub in exercise adaptation 66 
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 67 
Physiological induction of PGC-1α by exercise 68 
Muscle contraction activates a myriad of signaling cascades and many of those ultimately converge on 69 
PGC-1α to increase its expression levels and activity22. The AMP-dependent kinase (AMPK) and the 70 
mitogen-activated protein kinase (MAPK) p38 are both activated in response to contraction23, 24 and 71 
subsequently phosphorylate the PGC-1α protein25. Exercise also leads to de-acetylation and activation of 72 
PGC-1α. Different mechanisms regulating the acetylation level of PGC-1α have been proposed involving 73 
direct de-acetylation of PGC-1α by SIRT1 (silent mating type information regulator 2 homolog 1)26, 27 or 74 
inhibition of acetylation by exclusion of the acetyltransferase GCN5 from the nucleus28. 75 
Transcription of PGC-1α is regulated by the motor-neuron-induced rise in intracellular calcium, which 76 
leads to activation of calcium/calmodulin dependent protein kinases (CaMKs) and of the protein 77 
phosphatase calcineurin A (CnA)25, 29. Subsequently, the altered phosphorylation status of MEF2C/D and 78 
the cyclic AMP-responsive element binding protein (CREB) result in an activation of these transcription 79 
factors, binding to the PGC-1α promoter and induction of PGC-1α transcription. In addition, exercise-80 
induced activation of AMPK, p38, β2-adrenoceptor signaling, reactive oxygen and nitrogen species 81 
promote the transcription of PGC-1α30, 31. Three different splice variants of PGC-1α (PGC-1α-a, PGC-1α-82 
b and PGC-1α-c) are induced by exercise32. Compared with PGC-1α-a mRNA, PGC-1α-b or PGC-1α-c 83 
mRNAs are transcribed from a different exon 132. In mice, activation of AMPK increases the levels of all 84 
three PGC-1α isoforms, while β2-adrenoceptor signaling acts on the expression of PGC-1α-b and PGC-1α-85 
c32. Similarly, in human muscle PGC-1α-a and PGC-1α-b are both activated by AMPK, while β2-86 
adrenoceptor signaling seems to act mainly on PGC-1α-b33. Effects of other exercise-induced stimuli on 87 
the expression of different isoforms have not been examined to date. After bouts of endurance exercise, 88 
the total PGC-1α levels and its activity in skeletal muscle are consequently elevated. An auto-regulatory 89 
loop exists where PGC-1α further increases its own expression29. Once transcribed and activated PGC-1α 90 
carries out its various functions as summarized below. 91 
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PGC-1α in fiber type switching 92 
Type I and IIa slow-twitch, high-endurance muscle fibers express high levels of PGC-1α, which largely 93 
determine the fiber-type composition of skeletal muscle.  Ectopic expression of PGC-1α in skeletal muscle 94 
per se is sufficient to promote fiber-type switching34. Indeed, overexpression of PGC-1α shifts muscle 95 
appearance from a white to a reddish color34, promotes mitochondrial biogenesis of intramyofibrillar and 96 
subsarcolemmal mitochondria with concomitant reductions in myofibrillar volume35, alters myosin heavy 97 
chain (MHC) composition from MHC IIb and x towards more IIa and I34, switches metabolism from 98 
glycolytic to oxidative34 and slows down calcium handling35. Consequently, endurance performance is 99 
improved, while maximal force generation is significantly reduced35. Inversely, PGC-1α muscle-specific 100 
knock-out animals exhibit a shift from oxidative type I and IIa towards type IIx and IIb muscle fibers, and 101 
a reduced oxidative capacity36, 37. Thus, PGC-1α seems to drive fiber-type conversion in all its facets.  102 
PGC-1α in angiogenesis 103 
PGC-1α regulates the angiogenic vascular endothelial growth factor (VEGF). This induction of VEGF by 104 
PGC-1α is independent of the canonical hypoxia response pathway and hypoxia inducible factor (HIF). 105 
Instead, PGC-1α co-activates the orphan nuclear receptor ERRα (estrogen-related receptor α, NR3B1) on 106 
conserved binding sites found in the promoter and in a cluster within the first intron of the VEGF gene38. 107 
Consequently, PGC-1α promotes vascularization of skeletal muscle and thereby supports oxygen and 108 
nutrient supply. 109 
PGC-1α and myokines 110 
Skeletal muscle emerged furthermore as an endocrine organ, which releases myokines (cytokines from 111 
muscle) in response to exercise39. Given that PGC-1α mediates the effects of exercise to a high extent, the 112 
question arose, whether PGC-1α is involved in myokine production and release. Loss-of-function studies 113 
of PGC-1α gene expression in murine skeletal muscle revealed a systemic, low-grade, chronic 114 
inflammation characterized by elevated circulating levels of interleukin 6 (IL-6) and tumor necrosis factor 115 
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α (TNFα)36, 37. It remains currently unresolved, whether ectopic expression of PGC-1α, in turn, diminishes 116 
the production and release of these cytokines. 117 
PGC-1α in coordinating muscle metabolism and enhancing metabolic flexibility 118 
In respect to metabolism, PGC-1α exerts very versatile effects on skeletal muscle. It coordinately 119 
increases the expression of key regulators of lipid oxidation (MCAD; Medium Chain Acyl CoA 120 
Dehydrogenase, CPT1b; Carnitine palmitoyltransferase), Krebs cycle (Citrate synthase) and oxidative 121 
phosphorylation (Subunits of complexes I to IV)40.  122 
However, a careful regulation of this process is important since excessive or dysbalanced oxidative 123 
metabolism impairs insulin sensitivity. Acylcarnitines are generated when the amount of lipids fluxed into 124 
β-oxidation exceeds the capacity of the Krebs cycle and/or oxidative phosphorylation (OXPHOS)41. These 125 
detrimental lipid species are subsequently released into the circulation and contribute to the development 126 
of insulin resistance41-43. Similarly, the proton gradient that generates the mitochondrial membrane 127 
potential is a potential source of reactive oxygen species (ROS), which are also implicated in the etiology 128 
of insulin resistance44.  129 
Intriguingly, PGC-1α restrains these processes from excessive activation by concomitantly boosting the 130 
expression of negative regulators of lipid catabolism. The levels of inhibitors of lipid oxidation (ACC2), 131 
antagonists of ROS generation (UCP3; Uncoupling Protein and ANT; Adenine Nucleotide Translocator), 132 
and ROS-detoxifying enzymes are all elevated by PGC-1α40, 45. While the overall gene expression pattern 133 
is ambiguous, the net rates are nonetheless clearly showing an increased oxidation of fatty acids and an 134 
elevated mitochondrial membrane potential40. Therefore, the increased β-oxidation and the subsequent 135 
Krebs cycle and OXPHOS are tightly regulated and balanced by PGC-1α. The concomitant induction of 136 
both positive and negative regulators of fatty acid oxidation and OXPHOS through PGC-1α boosts 137 
metabolic flexibility and restrains excessive oxidation40.  138 
In addition, PGC-1α drives glucose uptake and determines fuel selection46. Glucose is diverted away from 139 
glycolysis and oxidation by inhibiting the activity of the pyruvate dehydrogenase complex through PDK4 140 
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(pyruvate dehydrogenase kinase 4)47, 48_ENREF_44. This is further substantiated by the reduced lactate 141 
production and glucose oxidation rates following overexpression of PGC-1α47. Rather glucose is used to 142 
replenish glycogen stores or shunted towards the pentose phosphate pathway to serve as substrate for de-143 
novo lipogenesis46, 47. Indeed, PGC-1α regulates the expression of the fatty acid synthase promoter through 144 
its interaction with liver x receptor α (LXRα, NR1H3)46. Furthermore, PGC-1α drives the expression of 145 
genes involved in lipid esterification into triglycerides46, 49_ENREF_39. Subsequently, intramyocellular 146 
lipids accumulate. PGC-1α is therefore a metabolic master regulator that induces and controls catabolic 147 
and anabolic pathways in skeletal muscle. 148 
Is there a role for muscle PGC-1α in energy expenditure? 149 
Total energy expenditure consists of various components. Principally, there are three major components of 150 
energy expenditure: basal metabolic rate (BMR), diet-induced thermogenesis (DIT) and activity 151 
thermogenesis (AT)50. BMR is the energy expended when an individual is lying at complete rest, in the 152 
morning, after sleep, in the postabsorptive state. In individuals with sedentary occupations BMR accounts 153 
for approximately 60% of total daily energy expenditure. DIT is the energy expenditure associated with 154 
the digestion, absorption, and storage of food and accounts for approximately 10–15% of total daily 155 
energy expenditure. AT has to be further separated into two sub-components: non-exercise activity 156 
thermogenesis (NEAT)51 (including fidgeting, muscle tone and posture maintenance, and other low-level 157 
physical activities of everyday life52) and exercise-related activity thermogenesis (ERAT). In the 158 
following we will mainly refer to energy expenditure in the sedentary state (i.e. the total of BMR, DIT and 159 
NEAT), and energy expenditure in response to exercise (ERAT). 160 
Skeletal muscle comprises 40% of body weight and, in the absence of physical activity, accounts for 20-161 
30% of energy expenditure53. The possibility arises that by altering skeletal muscle function, PGC-1α 162 
might increase energy expenditure in the sedentary state. Indeed adenoviral over-expression of PGC-1α in 163 
muscle cells in vitro elevates oxygen consumption and proton leak54, 55_ENREF_22. Consistently, 164 
physiological overexpression of PGC-1α increases oxygen consumption in isolated mitochondria56. In 165 
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mice with ectopic expression of PGC-1α in skeletal muscle, energy expenditure is, however, not 166 
elevated49, 57_ENREF_46, indicating that the increase in muscle oxygen consumption is possibly too 167 
moderate to influence whole body energy expenditure, not detectable or compensated. Thus an effect of 168 
PGC-1α on energy expenditure in the sedentary state -although likely- could so far not conclusively been 169 
demonstrated in vivo. 170 
Originally, PGC-1α was discovered as a mediator of adaptive thermogenesis in both brown fat and 171 
skeletal muscle of mice upon cold exposure58. The underlying mechanism in brown adipose tissue rapidly 172 
emerged. Brown adipose tissue is innervated by the sympathetic nervous system (SNS) and upon cold 173 
exposure, SNS nerve endings in BAT release noradrenaline, which activates β-adrenergic receptors. The 174 
subsequent induction of PGC-1α increases expression and activation of the uncoupling protein 1 (UCP1), 175 
dissipation of the electron gradient and an increase in oxygen consumption58, 59_ENREF_52. For a long 176 
time, similar mechanisms were believed to act in skeletal muscle and the discovery of the UCP1 177 
homologue UCP3 in muscle has further spurred this idea. In the meantime, conflicting results pertaining to 178 
the role of UCP3 as an uncoupler have been reported and interest has waned60-63_ENREF_52.  179 
The molecular mechanisms that mediate adaptive thermogenesis in skeletal muscle remain obscure. A 180 
model has been proposed implicating futile substrate cycling between lipid oxidation and de-novo 181 
lipogenesis in response to hormonal stimulation64, 65. Given that PGC-1α concomitantly promotes lipid 182 
oxidation and lipogenesis the possibility arises that PGC-1α has the potential to modulate oxygen 183 
consumption via substrate cycling upon adequate stimulation (e.g. exercise). During acute exercise, the 184 
PGC-1α-supported catabolism will prevail, leading to ATP generation for muscle contraction, while PGC-185 
1α-supported anabolism will further consume ATP post exercise. This temporal dissociation might allow 186 
optimal energy utilization during acute exercise and concomitantly energy dissipation during entire 187 
activity-rest cycles. 188 
ERAT constitutes the component of energy expenditure that can volitionally be modified by increasing the 189 
level of muscle work. Upon physical activity, skeletal muscle metabolism changes dramatically and 190 
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muscle oxygen consumption can account for up to 90% of the whole body oxygen uptake during this 191 
period53. Exercise depletes ATP, glycogen and IMCL stores and complements the action of PGC-1α, 192 
which, besides promoting oxidative metabolism, drives the refueling of energy stores. These concerted 193 
processes result in a high turnover of metabolic cycling and are thermogenic (Figure 2). In response to 194 
exercise, the respiratory exchange rate (RER) (ratio VCO2/VO2) is diminished and the peak oxygen 195 
consumption elevated in PGC-1α transgenic compared to wild-type animals57.  196 
Taken together, muscle PGC-1α in the absence of stimulation (cold exposure or exercise), seems not to 197 
affect whole body energy expenditure.  198 
Muscle PGC-1α in the regulation of whole body glucose homeostasis 199 
By modulating skeletal muscle function, PGC-1α plays an important role in regulating whole body 200 
glucose homeostasis. Indeed, muscle PGC-1α and overall metabolism seem to be highly interrelated. 201 
Abnormally low PGC-1α levels have been described in the skeletal muscle of type 2 diabetic patients and 202 
physically inactive individuals66, 67. Direct evidence for a role of muscle PGC-1α in controlling whole 203 
body glucose homeostasis derives from studies in mice where reduced or ablated expression of the gene 204 
encoding PGC-1α results in abnormal systemic glucose and insulin homeostasis36, 37. Inversely, transgenic 205 
mice with elevated muscle PGC-1α levels do not display improved whole body glucose homeostasis in the 206 
sedentary state, and even develop peripheral insulin resistance on a high-fat-containing diet, possibly due 207 
to increased lipid accumulation in skeletal muscle40, 49, 57_ENREF_15. 208 
Exercise is the real thing: PGC-1α- a partial exercise mimetic, not a substitute 209 
Exercise induces a complex pleiotropic response in skeletal muscle. Even one single bout of endurance 210 
exercise comprises changes in the expression of more than 900 genes68. To a considerably high extent 211 
PGC-1α mimics the effects of exercise, yet PGC-1α induction is not a replacement for exercise. In the 212 
following section we will highlight the most prominent differences between exercise as a physiological 213 
stimulus of muscle contraction and muscle-specific over-expression of PGC-1α as an “exercise mimetic”.  214 
 215 
  ‐ 12 ‐ 
Intriguingly, ectopic expression of PGC-1α can exert positive feedback on some of its alleged upstream 216 
activators. The neuromuscular junction program is regulated by PGC-1α69. Furthermore, the activity of 217 
calcium-dependent signaling pathways via prolongation of myoplasmic calcium transients is increased by 218 
PGC-1α and similarly PGC-1α activates the transcription of nitric oxide synthase (inducible and 219 
endothelial, but not neuronal), which promotes elevated levels of nitric oxide35, 70. By contrast, some other 220 
upstream activators, namely AMPK and p38 are not affected by ectopic expression of PGC-1α49, 71. On the 221 
contrary, glycogen levels are elevated in response to PGC-1α and an inverse correlation between muscle 222 
glycogen content and AMPK activity has been established47, 72, 73_ENREF_34. AMPK has a glycogen 223 
binding domain on its β-subunit and there is evidence that glycogen- directly or indirectly- inhibits AMPK 224 
activity74. Furthermore, by tightly balancing ROS levels, PGC-1α might antagonize the activation of ROS-225 
dependent signaling pathways in skeletal muscle40, 75.  226 
Those signaling pathways (AMPK, ROS and p38), however, mediate contraction-induced glucose uptake 227 
and metabolism. Indeed, the inhibition of AMPK abolishes glucose uptake in response to muscle 228 
contraction and similarly, inhibition of ROS-p38 prevents glucose uptake induced by muscle stretching76, 229 
77. It could be argued that the higher GLUT4 (Glucose Transporter 4) content in muscles of PGC-1α 230 
transgenic animals compensates the lack of AMPK and ROS-p38 mediated glucose uptake. However, the 231 
relative increase in glucose uptake is smaller in transgenic animals with ectopic expression of PGC-1α 232 
(~50%) than the increase in response to contraction (> 100%)46, 78-80.  233 
 234 
Oscillations of muscle glycogen and triglyceride levels occur with physical activity-rest cycles. Energy 235 
stores are depleted during physical activity and replenished during rest. Contraction and epinephrine 236 
activate the lipolysis of IMCL by activating hormone sensitive lipase (HSL) and by promoting the 237 
translocation of HSL to IMCL in skeletal muscle, thereby contributing to the temporary reduction in 238 
muscular triglyceride stores81, 82. Similarly, exercise stimulates glycogen breakdown83. 239 
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In contrast, PGC-1α, besides promoting oxidative capacity, drives de-novo lipogenesis and lipid storage 240 
into IMCL in the sedentary state46. Furthermore, PGC-1α stimulates glycogen synthesis and restrains 241 
glycogen breakdown47.  242 
Ectopic expression of PGC-1α in the absence of physical activity thus results in a stalling of glycogen and 243 
triglyceride stores at high levels in skeletal muscle46, 47. Analogously to an imbalance in energy intake and 244 
expenditure, the absence of physical activity leads to an imbalance between physical activity and rest. 245 
However, these physical activity-rest cycles are the core catalysts to physiologically break the stalling of 246 
muscle glycogen and triglyceride stores at high levels18.  247 
 248 
Moreover, energy expenditure of muscle is high during exercise, due to the low efficiency of muscular 249 
contraction (∼25%) and thus the dissipation of the bulk of energy as heat. Therefore, although PGC-1α 250 
increases energy expenditure in muscle cells54, 55, this contribution to total energy expenditure might be 251 
relatively low in the absence of physical activity. Indeed, whole body energy expenditure is not elevated 252 
in sedentary mice with ectopic expression of PGC-1α49. 253 
 254 
Importantly, exercise also affects other tissues and thus alters whole-body glucose homeostasis differently 255 
than muscle-specific activation of PGC-1α alone84. An acute bout of exercise is associated with changes in 256 
the metabolism of liver and adipose tissue that result in an increased provision of fuel for the contracting 257 
muscle. The liver increases the release of glucose (initially derived from glycogenolysis and later from 258 
gluconeogenesis) into the circulation and adipose tissue increases the hydrolysis triglycerides and the 259 
release of long chain nonesterified fatty acids (LCFA) into the circulation. A large body of evidence from 260 
both humans and experimental animals has linked these changes to activation of the sympathetic nervous 261 
system (norepinephrine) and to increases in plasma levels of glucagon and epinephrine74. Regular exercise 262 
induces increases in AMPK and ACC phosphorylation in visceral adipose tissue and liver74. Despite the 263 
scarcity of literature concerning the heart, similar effects are expected to occur in the heart, where acute 264 
bouts of exercise promote elevated AMPK phosphorylation85. Furthermore, chronic exercise affects 265 
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mitochondrial biogenesis and thus respiration not only in skeletal muscle, but also in adipose tissue, liver, 266 
brain, kidney and cardiac muscle86-89_ENREF_84. 267 
 268 
It is thus conceivable, that PGC-1α increases the capacity of skeletal muscle for substrate catabolism and 269 
anabolism, but does probably not substantially alter whole body energy expenditure and metabolic cycling 270 
in the absence of exercise (Figure 2).  271 
 272 
Current limitations for pharmaceutical targeting of PGC-1α 273 
Our current knowledge of the action of PGC-1α derives mainly from genetic mouse models. The hormetic 274 
effect of PGC-1α on skeletal muscle function and integrity emerged as an important insight from these 275 
studies in transgenic animals 90. In mouse models with moderate, physiological expression of PGC-1α 276 
(levels comparable to those of an oxidative soleus muscle), PGC-1α was deemed a beneficial modulator of 277 
muscle plasticity, while higher levels resulted in adverse effects such as impairments in muscular glucose 278 
homeostasis and atrophy90-92. 279 
 280 
A future challenge is the development of safe drugs that increase PGC-1 levels specifically in skeletal 281 
muscle to exactly predefined levels93. Currently known substances that pharmacologically target PGC-1α 282 
are either unspecific or associated with side effects. Metformin and other agents which stimulate AMP-283 
activated kinase, PPARδ (Peroxisome Proliferator-Activated Receptor) agonists, corticosteroids and β-284 
adrenergic agonists have all been shown to increase PGC-1α94. However, they are all unspecific and 285 
furthermore affect PGC-1α levels in the liver, where PGC-1α enhances gluconeogenesis and hepatic 286 
glucose output95. Moreover, they potentially also activate PGC-1α in the heart, thereby leading to 287 
derangements of mitochondrial ultrastructure and development of cardiomyopathy96. The cardiomyopathy 288 
is characterized by an increase in ventricular mass and chamber dilatation and seems to be reversible96. 289 
 290 
Conclusion and outlook 291 
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PGC-1α evidentially confers a trained state upon skeletal muscle and increases the metabolic capacity 292 
without inflicting per se positive effects on body weight control and glucose homeostasis when 293 
exclusively augmented in this tissue25, 40, 49, 57. However, elevated levels of PGC-1α in skeletal muscle can 294 
serve to support and facilitate exercise in physically inactive subjects. This is essentially based on the 295 
direct demonstration that sedentary mice with ectopic expression of PGC-1α have a higher endurance 296 
capacity when they are forced to run and their isolated muscles are resistant to fatigue34, 35, 57_ENREF_33. 297 
Many additional effects of exercise, which are crucial for metabolic health, cannot simply be mimicked by 298 
the sole induction of PGC-1α. A trigger, such as exercise, is mandatory to increase energy expenditure and 299 
to initiate metabolic cycling. In the absence of this trigger, PGC-1α might even exert detrimental effects 300 
by promoting stalling of muscular energy stores at high levels46, 47. 301 
 302 
The combination of targeting PGC-1α to facilitate exercise and a moderate, tolerable level of exercise to 303 
avoid energy conservation and initiate metabolic cycling might constitute a promising approach for the 304 
treatment of obesity, obesity-associated comorbidities and for long-term body weight control. Importantly, 305 
this approach is not restricted to patients with metabolic impairments, but is broadly applicable for other 306 
diseased states where weight regain can occur, but where the health status of the patient precludes 307 
achievement of adequate levels of physical activity. More specifically, such weight regain in the form of 308 
preferential catch-up-fat is well documented after weight loss due to malnutrition, cancer, septic shock or 309 
AIDS and thus constitutes a general phenomenon related to weight loss17.  310 
 311 
The potential for such combined treatments might be enormous. The pinnacle for the global prevalence of 312 
metabolic disorders has definitely not yet been reached. Future technical developments will further 313 
decrease the necessity for daily physical activity and lead to an even more sedentary behavior. An entire 314 
evolving scientific branch is dedicated to the investigation of such ‘inactivity physiology‘97, 98. A recent 315 
review on the subject addresses the risk of sitting in decreasing energy expenditure by diminishing non-316 
exercise activity thermogenesis and favoring the development of metabolic diseases and a recent study 317 
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reported attenuated insulin sensitivity in healthy, non-exercising subjects who went from a normal to a 318 
low level of ambulatory activity for 2 wks97, 99_ENREF_77. In the light of the increasing prevalence of 319 
metabolic disorders, the use of adjuvants to enhance exercise effects in people with a low drive to move 320 





Conflict of interest 326 
The authors declare no conflict of interest. Our research is supported by grants from the Swiss National 327 
Science Foundation (SNF PP00A-110746), the Muscular Dystrophy Association USA (MDA), the 328 
SwissLife ‘Jubiläumsstiftung für Volksgesundheit und medizinische Forschung‘, the Swiss Society for 329 
Research on Muscle Diseases (SSEM), the Swiss Diabetes Association, the Roche Research Foundation, 330 
the United Mitochondrial Disease Foundation (UMDF), the Association Française contre les Myopathies 331 



































































































































































































































































































































































































Figure 1: Cycles of famine/feast (outer cycle) and physical activity/rest (inner cycle). Reductions in 709 
energy intake (famine or dieting) induce weight and adipose tissue loss. Concomitantly, the reduced food 710 
availability prompts ambulatory activity for the purpose of gathering and hunting. This additionally 711 
contributes to weight and fat mass loss. Moreover, physical activity depletes ATP, glycogen and IMCL 712 
stores in skeletal muscle. The scarcity of energy ultimately activates a thrifty program in skeletal muscle 713 
to conserve energy.  714 
If food becomes available (feast) and dieting is abandoned, the thrifty program supports the replenishment 715 
of energy stores and weight regain, which preferentially occurs in the form of catch-up fat and which is 716 
driven by a hyperinsulinemic state. Satiety signals during the period of feast automatically lead to rest, 717 
which further supports adipose tissue regain and the restoration of glycogen and IMCL pools in the 718 
muscle. 719 
Exercise can counteract the energy conservation in skeletal muscle and prevent weight regain. In addition, 720 
regular exercise promotes the turnover of ATP, glycogen and IMCLs. The effects of exercise are indicated 721 
as dotted lines. 722 
Figure 2: PGC-1α and exercise. Acute bouts of exercise raise myoplasmic calcium levels, increase the 723 
activity of p38 and AMPK, and generate reactive oxygen and nitrogen species, which ultimately all 724 
culminate in activation of PGC-1α. Subsequently, PGC-1α carries out its various functions.  725 
The ectopic expression of PGC-1α alone- even in the absence of exercise- is largely sufficient to mimic 726 
exercise-like responses. PGC-1α favors higher myoplasmic calcium and nitric oxide levels by slowing 727 
down calcium handling and inducing nitric oxide synthase expression, respectively. Muscle PGC-1α 728 
promotes mitochondrial biogenesis, fiber-type switching and angiogenesis. Furthermore, PGC-1α 729 
increases glucose uptake in order to generate ATP for later muscle contraction as well as to fuel glycogen 730 
  ‐ 27 ‐ 
and IMCL stores. In the absence of physical activity, this will result in elevated levels of ATP, glycogen 731 
and IMCLs.  732 
In contrast to the sole ectopic expression of PGC-1α, the stimulation of p38, AMPK and ROS by muscle 733 
contraction, further increases glucose uptake to quickly generate additional ATP. Moreover, exercise 734 
depletes ATP, glycogen and IMCL stores during muscle contraction and thereby induces metabolic 735 
cycling between energy depletion during physical activity and energy refueling post-exercise. Due to the 736 
low efficiency of muscle work around 75% of the energy is dissipated as heat and therefore these 737 
processes increase energy expenditure. Upon exercise, the sympathetic nervous system is activated and 738 
releases epinephrine and other hormones. Subsequent lipolysis in adipose tissue diminishes fat mass. In 739 
addition, skeletal muscle releases myokines that can act on other tissues.   740 
Continuous lines and boxes with continuous lines: exercise-effects mediated by PGC-1α. Dotted lines and 741 
boxes with dotted lines: effects mediated by exercise, but not imitable by ectopic expression of PGC-1α.  742 
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